Trial · NCT07072208
Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL
NCT07072208, Not applicable, Recruiting, The First Affiliated Hospital of Soochow University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL. Trials, record NCT07072208. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07072208
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL
- NCT number
- NCT07072208
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 43 participants, estimated
- Lead sponsor
- The First Affiliated Hospital of Soochow University
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Induction therapy-Pro regimen, Consolidation therapy-Pro-pola regimen
- First posted
- 2025-07-18
- Last updated
- 2025-07-18
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete response rate(CRR) | At the end of 6 cycles of Pro-pola regimen (each cycle is 21 days) | The rate of patients who achieved CR after 6 cycles of Pro-pola regimen |
| Secondary | Objective response rate(ORR) | At the end of 6 cycles of Pro-pola regimen (each cycle is 21 days) | The rate of patients who achieved CR or PR after 6 cycles of Pro-pola regimen |
| Secondary | 2-year progression-free survival(PFS) | From the enrollment to 2-year after the treatment of last patient | PFS will be assessed from the start of the treament to date of progression, relapse, death or end of follow-up. |
| Secondary | 2-year overall survival(OS) | From the enrollment to 2-year after the treatment of last patient | OS will be assessed from the start the treatment to date of death or end of follow-up. |
| Secondary | Main adverse reactions | From the enrollment to 1 months after 6 cycles of Pro-pola regimen of the last patient (each cycle is 21 days) | The safety of the therapeutic regimen measured by the major adverse events. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07072208
GET https://conductscience.org/api/trials/v1/NCT07072208/registered